



Current Agreements

Dealdoc

Licensing and distribution agreement for nitroglycerin sublingual powder formulation

Espero Biopharma

Pohl Boskamp

Sep 16 2015

Licensing and distribution agreement for nitroglycerin sublingual powder formulation

Companies:	Espero Biopharma Pohl Boskamp
Announcement date:	Sep 16 2015
Deal value, US\$m:	n/d

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Sep 16 2015
Industry sectors:	Drug delivery Generic pharma Pharmaceutical
Compound name:	Nitroglycerin
Exclusivity:	Exclusive
Asset type:	Product
Therapy areas:	Cardiovascular » Angina
Technology types:	Drug delivery » Transmucosal » Inhaled Small molecules
Deal components:	Distribution Licensing
Stages of development:	Marketed
Geographic focus:	North America » United States

Financials

Deal value, US\$m:	n/d
---------------------------	-----

Termsheet

Espero Pharmaceuticals announced the signing of an exclusive Licensing and Distribution Agreement with G. Pohl-Boskamp for its new nitroglycerin sublingual powder formulation for acute relief of an attack or prophylaxis of angina pectoris for the U.S. market.

Press Release

Espero Pharmaceuticals Announces Exclusive Licensing And Distribution Agreement

September 16, 2015/ Press Release

JACKSONVILLE, FL—(BUSINESS WIRE)—Espero Pharmaceuticals, Inc., (<http://www.esperopharma.com>) a privately held specialty pharmaceutical company, today announced the signing of an exclusive Licensing and Distribution Agreement with G. Pohl-Boskamp GmbH & Co. KG ("Pohl-Boskamp"), a fully-integrated German pharmaceutical company with a 175 year operating history, for its new nitroglycerin sublingual powder formulation for acute relief of an attack or prophylaxis of angina pectoris for the U.S. market.

Pohl-Boskamp is the owner of the New Drug Application (NDA) for Nitrolingual® Pumpspray approved by the United States Food & Drug Administration (FDA) in 1997. Pohl-Boskamp has developed a newly patented formulation of nitroglycerin, nitroglycerin oral powder for sublingual administration. Nitroglycerin is a well-known NO-donor and sublingual routes in particular, are established for medicinal use in the

U.S., the European Union and non-European countries, with recognized efficacy in patients with angina pectoris and an acceptable level of safety.

“Espero will assist our partner, Pohl-Boskamp, and support the submission of the NDA for this new nitroglycerin sublingual powder formulation to the FDA which is required for marketing approval,” said Quang Pham, CEO.

“This is a major achievement for our company,” said Marianne Boskamp, CEO of Pohl-Boskamp. “We believe our new formulation of nitroglycerin sublingual powder will be a more convenient method of delivery for both hospitals, clinicians and patients alike. We look forward to working with Espero as we seek FDA approval for our latest product.”

About Espero Espero Pharmaceuticals, Inc., headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories.

About G. Pohl-Boskamp GmbH & Co KG Pohl-Boskamp is a privately owned business active in the international pharmaceutical market for 175 years with commercialized products in more than 45 countries. Pohl-Boskamp focuses on collaborating closely with partners abroad and developing products that positively impact patients' quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders and dermatology. For more information visit <http://www.pohl-boskamp.com/en/>.

Filing Data

Not available.

Contract

Not available.